REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
09/15/2025
Back to search
Official data from USPTO
ONCOHEROES BIOSCIENCES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
ONCOHEROES BIOSCIENCES
ST13
US500000088977616Class
42
Filing
88977616
Registration
6153404
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
09/16/2025
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
01/07/2019
Registration date
09/15/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/15/2020
Last transaction
09/16/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
12/13/2018
First use in commerce
01/02/2019
Drawing code
4
Owner type
03
Owner location
Brookline, MA
Examiner
BELL, MARLENE
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Oncokids Biosciences Inc.
Representatives
Jonathan Eric Agin JONATHAN ERIC AGIN, LLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific and technological services and researchdevelopment and design in the field of biotechnology and cancer drug development; Industrial analysis and research services in the field of biotechnology and cancer therapeutics; Consultancy services relating to technological research; Technical research services in the field of biotechnology and cancer drug development; Laboratory research in the field of chemistry; Chemical research; Scientific research and development services; Consultancy services relating to technological research in the field of cancer; Research laboratory services in the field of cancer drug discovery; Medical and pharmacological research services; research and development for others in the field of cancer drug development; Laboratory research in the field of biotechnology and cancer drug development; Scientific research; Research and development in the field of biotechnology; Research and development of new products for others; Clinical trialscreating and conducting clinical trials for cancer patients and others; Biological research; Development of diagnostic apparatus; Product design and development in the field of cancer; Research and development in the field of biotechnology and cancer
Publications
History of USPTO decisions and trademark events.
33 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/15/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/30/2020
PUBO
PUBLISHED FOR OPPOSITION
06/30/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/23/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
05/18/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/18/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
05/18/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/18/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
04/27/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/24/2020
DRRR
DIVISIONAL REQUEST RECEIVED
04/09/2020
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
04/09/2020
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
01/21/2020
ALIE
ASSIGNED TO LIE
01/20/2020
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
01/18/2020
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
01/18/2020
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
01/18/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/18/2019
GNRT
NON-FINAL ACTION E-MAILED
08/18/2019
CNRT
NON-FINAL ACTION WRITTEN
08/18/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/20/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/19/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/19/2019
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
03/28/2019
ALIE
ASSIGNED TO LIE
03/27/2019
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
03/27/2019
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
03/27/2019
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
03/27/2019
DOCK
ASSIGNED TO EXAMINER
03/22/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/28/2019
NWAP
NEW APPLICATION ENTERED
01/10/2019
Continuous trademark protection
Get notified about every new filing that threatens ONCOHEROES BIOSCIENCES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.